All In Biotech

Drug Trial Radar · NCT06140303

SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)

Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers. Closure Obtained With Vascularized Epithelial Regeneration for DFUs With SkinTE® II (COVER DFUS II)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Feb 22, 2024

Primary completion

Jan 30, 2026

Study completion Apr 30, 2026

Sponsor

Lead sponsor
PolarityTEIndustry
Sponsor type
Industry
Collaborators
Professional Education and Research Institute
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of SkinTE for treatment of Wagner grade 1 diabetic foot ulcers.

Conditions

  • Diabetic Foot

Interventions

  • SkinTEBiological

    SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.

  • ControlOther

    Standard care is defined in this protocol to include the following: * Debridement * Collagen dressing * Local offloading * Foam * Multi-layer compression dressing * Off-loading device such as a controlled ankle motion (CAM) boot

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of index ulcers closedTime frame: 12 weeks

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Titan Clinical Research

    Mesa, Arizona

  • Center for Clinical Research

    Castro Valley, California

  • Limb Preservation Platform, Inc.

    Fresno, California

  • Angel City Research

    Los Angeles, California

  • Clemente Clinical Research Inc.

    Los Angeles, California

  • Center for Clinical Research

    San Francisco, California

  • Clemente Clinical Research Inc.

    Santa Ana, California

  • ILD Research

    Vista, California

  • Las Mercedes Medical Research, Inc.

    Hialeah, Florida

  • Doctors Research Network

    Miami, Florida

  • DMI Research

    Pinellas Park, Florida

  • Barry University Clinical Research

    Tamarac, Florida

  • FASMA - Hagerstown

    Hagerstown, Maryland

  • Viable Research Management

    Henderson, Nevada

  • Northwell Health, Inc.

    New Hyde Park, New York

  • Mount Sinai West Hospital

    New York, New York

  • LEIRT (Lower Extremity Institute for Research and Therapy)

    Boardman, Ohio

  • Cutting Edge Research LLC

    Circleville, Ohio

  • LEIRT (Lower Extremity Institute for Research and Therapy)

    East Liverpool, Ohio

  • Cutting Edge Research LLC

    Grove City, Ohio

  • Perfizien Clinical Research LLC.

    Houston, Texas

  • Baylor Scott & White Health

    Plano, Texas

  • Foot and Ankle Specialists of the Mid-Atlantic

    Salem, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.